The peripheral T-cell lymphoma: can we pivot from the chemotherapy-predicated paradigm?

Abstract

Peripheral T-cell lymphomas (PTCL) are uncommon and aggressive diseases that are difficult to study. Combination chemotherapy such as cyclophosphamide, doxorubicin, vincristine, and prednisone has been the mainstay of treatment for almost 30 years, but outcomes remain poor. The development of new targeted therapies is changing the landscape of how we treat patients with these difficult diseases. For instance, the addition of brentuximab vedotin to combination chemotherapy enhanced the outcomes in patients with CD30-positive anaplastic large cell lymphomas, but there is still a need for better therapies in the other numerous subtypes. Here we discuss the data for the existing treatment paradigm of PTCL as well as the merits of shifting toward a chemotherapy-free approach.

Keywords

Peripheral T-cell lymphomas / PTCL / chemotherapy-free / epigenetics / targeted therapy

References

[1] Swerdlow SH,Pileri SA.The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Blood2016;127:2375-90 PMCID:PMC4874220

[2] Vose J,Weisenburger D.International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.J Clin Oncol2008;26:4124-30

[3] Czuczman MS,Witzig TE.The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.Br J Haematol2011;154:477-81

[4] Bachy E,Thieblemont C.Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-Cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA).J Clin Oncol2022;40:242-51

[5] Shustov AR,Barta SK.CHOP in combination with pralatrexate, a novel folate analogue metabolic inhibitor in patients with previously untreated peripheral t-cell lymphoma (PTCL): interim results of the phase 1 trial.Blood2016;128:5355-5355

[6] Horwitz S,Pro B.Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.Lancet2019;393:229-40 PMCID:PMC6436818

[7] Ma H,Falchi L.Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials.Hematol Oncol2020;38:51-8

[8] Stuver RN,Schwartz M.Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry.Am J Hematol2019;94:641-9 PMCID:PMC7928240

[9] Choi J,Walradt T.Genomic landscape of cutaneous T cell lymphoma.Nat Genet2015;47:1011-9 PMCID:PMC4552614

[10] van Doorn R,Dijkman R.Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome.Blood2009;113:127-36

[11] Dunn J,Tu WJ,Rao S.Multi-layered epigenetic mechanisms contribute to transcriptional memory in T lymphocytes.BMC Immunol2015;16:27 PMCID:PMC4422045

[12] Antignano F.Regulation of CD4 T-cell differentiation and inflammation by repressive histone methylation.Immunol Cell Biol2015;93:245-52

[13] Iqbal J,Wang C.Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.Blood2014;123:2915-23 PMCID:PMC4014836

[14] Palomero T,Khiabanian H.Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.Nat Genet2014;46:166-70 PMCID:PMC3963408

[15] Ji MM,Huang JY.Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.Haematologica2018;103:679-87

[16] Sandell RF,Feldman AL.Genetic landscape and classification of peripheral T Cell lymphomas.Curr Oncol Rep2017;19:28 PMCID:PMC5517131

[17] Quivoron C,Della Valle V.TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis.Cancer Cell2011;20:25-38

[18] Genovese G,Handsaker RE.Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.N Engl J Med2014;371:2477-87 PMCID:PMC4290021

[19] Bowman RL.TET2 in normal and malignant hematopoiesis.Cold Spring Harb Perspect Med2017;7:a026518 PMCID:PMC5538403

[20] Couronné L,Bernard OA.TET2 and DNMT3A mutations in human T-cell lymphoma.N Engl J Med2012;366:95-6

[21] Lemonnier F,Parrens M.Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.Blood2012;120:1466-9

[22] Odejide O,Lane AA.A targeted mutational landscape of angioimmunoblastic T-cell lymphoma.Blood2014;123:1293-6 PMCID:PMC4260974

[23] Muto T,Hasegawa N.Myelodysplastic syndrome with extramedullary erythroid hyperplasia induced by loss of Tet2 in mice.Leuk Lymphoma2015;56:520-3

[24] Ichiyama K,Wang X.The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells.Immunity2015;42:613-26 PMCID:PMC4956728

[25] Cortés JR.Biology and molecular pathogenesis of mature T-Cell lymphomas.Cold Spring Harb Perspect Med2021;11:a035402 PMCID:PMC7928237

[26] Scourzic L,Pedersen MT.DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.Leukemia2016;30:1388-98 PMCID:PMC4869893

[27] Cairns RA,Lemonnier F.IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma.Blood2012;119:1901-3 PMCID:PMC3293643

[28] Ward PS,Wise DR.The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.Cancer Cell2010;17:225-34 PMCID:PMC2849316

[29] Wang C,Gong Q.IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma.Blood2015;126:1741-52 PMCID:PMC4600014

[30] Ridley AJ.RhoA, RhoB and RhoC have different roles in cancer cell migration.J Microsc2013;251:242-9

[31] Jaffe AB,Hall A.Human CNK1 acts as a scaffold protein, linking Rho and Ras signal transduction pathways.Mol Cell Biol2004;24:1736-46 PMCID:PMC344169

[32] Morin P,Olson MF.Constitutively active RhoA inhibits proliferation by retarding G(1) to S phase cell cycle progression and impairing cytokinesis.Eur J Cell Biol2009;88:495-507 PMCID:PMC2750871

[33] Sakata-Yanagimoto M,Yoshida K.Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.Nat Genet2014;46:171-5

[34] Yoo HY,Lee SH.A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.Nat Genet2014;46:371-5

[35] Ng SY,Stevenson K.RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice.Blood2018;132:935-47

[36] Cortes JR,Couronné L.RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis.Cancer Cell2018;33:259-273.e7 PMCID:PMC5811310

[37] Zang S,Yang H.Mutations in 5-methylcytosine oxidase TET2 and RhoA cooperatively disrupt T cell homeostasis.J Clin Invest2017;127:2998-3012 PMCID:PMC5531410

[38] Boddicker RL,Dasari S.Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.Blood2016;128:1234-45 PMCID:PMC5009513

[39] Fujisawa M,Nishizawa S.Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma.Leukemia2018;32:694-702 PMCID:PMC5843900

[40] Vallois D,Morin RD.Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.Blood2016;128:1490-502

[41] Rohr J,Huo J.Recurrent activating mutations of CD28 in peripheral T-cell lymphomas.Leukemia2016;30:1062-70 PMCID:PMC5688878

[42] Manso R,González-Rincón J.Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas.Haematologica2015;100:e25-7 PMCID:PMC4281331

[43] Streubel B,Willheim M,Chott A.Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma.Leukemia2006;20:313-8

[44] Huang Y,Dupuis J.Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas.Am J Surg Pathol2009;33:682-90 PMCID:PMC4838638

[45] Feldman AL,Law ME.Overexpression of syk tyrosine kinase in peripheral T-cell lymphomas.Leukemia2008;22:1139-43 PMCID:PMC2778211

[46] Pechloff K,Ferch U.The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma.J Exp Med2010;207:1031-44 PMCID:PMC2867290

[47] Watatani Y,Miyoshi H.Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling.Leukemia2019;33:2867-83

[48] Fisher RI,Dahlberg S.Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin’s lymphoma.N Engl J Med1993;328:1002-6

[49] Abramson JS,Kroll-Desrosiers AR.Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.Ann Oncol2014;25:2211-7 PMCID:PMC4481543

[50] Schmitz N,Ziepert M.Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-hodgkin lymphoma study group.Blood2010;116:3418-25

[51] Cederleuf H,Jerkeman M,d’Amore F.The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.Br J Haematol2017;178:739-46

[52] Deng S,Shen J.Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis.Onco Targets Ther2019;12:2335-42 PMCID:PMC6445243

[53] Lai GM,Mickley LA,Bates SE.P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines.Int J Cancer1991;49:696-703

[54] Horwitz S,Pro B.The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.Ann Oncol2022;33:288-98

[55] Coiffier B,Briere J.CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.N Engl J Med2002;346:235-42

[56] Wang ES,She Y,Sirotnak FM.Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.Leuk Lymphoma2003;44:1027-35

[57] O’Connor OA,Pinter-Brown L.Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.J Clin Oncol2011;29:1182-9

[58] Advani RH,Lechowicz MJ.A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.Br J Haematol2016;172:535-44 PMCID:PMC5642048

[59] Coiffier B,Prince HM.Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.J Clin Oncol2012;30:631-6

[60] Foss F,Pro B.Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.J Hematol Oncol2016;9:22

[61] Foss F,Pro B.Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.J Hematol Oncol2017;10:154 PMCID:PMC5603163

[62] Chiappella A,Re A.Adding romidepsin to CHOEP in first line treatment of peripheral T-Cell lymphomas does not improve the response rate: final analysis of phase II PTCL13 study.Blood2021;138:134-134

[63] Ruan J,Mehta-Shah N.High Rates of remission with the initial treatment of oral azacitidine plus CHOP for peripheral T-Cell lymphoma (PTCL): clinical outcomes and biomarker analysis of a multi-center phase II study.Blood2021;138:138.

[64] Wulf GG,Ziepert M.Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.Leukemia2021;35:143-55

[65] Lemonnier F,Beldi-Ferchiou A.Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.Blood Adv2021;5:539-48 PMCID:PMC7839364

[66] Haverkos B,Kamdar M.A pilot study using nivolumab in combination with standard of care chemotherapy in newly diagnosed peripheral T-Cell lymphomas.Blood2021;138:2444

[67] Mak V,Chhanabhai M.Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.J Clin Oncol2013;31:1970-6

[68] Ogura M,Hatake K.Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.J Clin Oncol2014;32:1157-63

[69] O’Connor OA,Masszi T.Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study.J Clin Oncol2015;33:2492-9 PMCID:PMC5087312

[70] Horwitz SM,Bartlett NL.Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.Blood2014;123:3095-100 PMCID:PMC4425442

[71] Shi Y,Hong X.Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.Ann Oncol2015;26:1766-71

[72] Maruyama D,Maeda Y.Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.Cancer Sci2017;108:2061-8 PMCID:PMC5623731

[73] Hong X,Huang H.Pralatrexate in chinese patients with relapsed or refractory peripheral T-Cell lymphoma: a single-arm, multicenter study.Target Oncol2019;14:149-58 PMCID:PMC6453867

[74] Piekarz RL,Turner M.Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.J Clin Oncol2009;27:5410-7 PMCID:PMC2773225

[75] Whittaker SJ,Kim EJ.Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.J Clin Oncol2010;28:4485-91

[76] Maruyama D,Ogura M.Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.Int J Hematol2017;106:655-65

[77] Kim SJ,Ki CS,Kim JS.Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.Ann Oncol2016;27:508-13

[78] Kim JH,Park C.Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications.Antiviral Res2021;189:105063

[79] Sawas A,Shustov A.Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.Leuk Lymphoma2020;61:2003-7

[80] Maruyama D,Uchida T.Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.Ann Hematol2019;98:131-42 PMCID:PMC6334730

[81] Phillips AA,Hermine O.Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.Haematologica2019;104:993-1003 PMCID:PMC6518882

[82] Fuji S,Utsunomiya A.Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-Cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality.J Clin Oncol2016;34:3426-33

[83] Saillard C,Derrieux C.Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.Hematol Oncol2017;35:864-8

[84] Cheminant M,Kosmider O.Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma.Br J Haematol2015;168:913-6

[85] Lemonnier F,Sujobert P.Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.Blood2018;132:2305-9

[86] Horwitz SM,Pro B.Dose optimization of duvelisib in patients with relapsed or refractory peripheral T-Cell lymphoma from the phase 2 primo trial: selection of regimen for the dose-expansion phase. Blood 2019;134:1567.

[87] Brammer JE,Zain J.Duvelisib in patients with relapsed/refractory peripheral T-Cell lymphoma from the phase 2 Primo trial: results of an interim analysis.Blood2021;138:2456-2456.

[88] Huen A,Zain J.Phase I/Ib study of Tenalisib (RP6530), a Dual PI3K δ/γ inhibitor in patients with relapsed/refractory T-Cell lymphoma.Cancers (Basel)2020;12:2293 PMCID:PMC7463651

[89] Barta SK,MacFarlane AW.Phase II study of the PD-1 Inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma.Clin Lymphoma Myeloma Leuk2019;19:356-364.e3

[90] Bennani NN,Atherton P.A phase II study of nivolumab in patients with relapsed or refractory peripheral T-Cell lymphoma. Blood 2019;134:467-467.

[91] Ratner L,Janakiram M.Rapid progression of adult T-Cell leukemia-lymphoma after PD-1 inhibitor therapy.N Engl J Med2018;378:1947-8

[92] Rauch DA,Janakiram M.Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade.Blood2019;134:1406-14 PMCID:PMC6839957

[93] Shi Y,Wang Z.Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002).J Hematol Oncol2021;14:12 PMCID:PMC7802130

[94] Li X,Zhang M.Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.J Hematol Oncol2018;11:15 PMCID:PMC5793390

[95] Kwong YL,Tan D.PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.Blood2017;129:2437-42

[96] Kim SJ,Cho I,Kim WS.Comparison of efficacy of pembrolizumab between epstein-barr virus-positive and -negative relapsed or refractory non-hodgkin lymphomas.Cancer Res Treat2019;51:611-22

[97] Kim SJ,Laurensia Y.Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.Blood2020;136:2754-63

[98] Horwitz SM,Ye JC.Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with relapsed/refractory peripheral T-Cell lymphoma. Blood 2021;138:622

[99] O’Connor OA,Jacobsen ED.Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-Cell lymphoma.J Clin Oncol2019;37:613-23 PMCID:PMC6494247

[100] Foss FM,Horwitz SM.A global phase 2 study of valemetostat tosylate (valemetostat) in patients with relapsed or refractory (R/R) peripheral T-Cell lymphoma (PTCL), including R/R adult T-Cell leukemia/lymphoma (ATL) - valentine-PTCL01. Blood 2021;138:2533

[101] Yoshimitsu M,Makita S.Pivotal phase 2 study of the EZH1 and EZH2 inhibitor valemetostat tosylate (DS-3201b) in patients with relapsed or refractory adult T-Cell leukemia/lymphoma.Blood2021;138:303-303

[102] Marchi E,Amengual JE.The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma.Br J Haematol2015;171:215-26

[103] Falchi L,Klein S.Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.Blood2021;137:2161-70

[104] Jain S,Zullo KM.Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma.Clin Cancer Res2015;21:2096-106

[105] Amengual JE,Lue J.A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma.Blood2018;131:397-407 PMCID:PMC5790128

[106] Iyer SP,Ai WZ.Safety and efficacy of tenalisib given in combination with romidepsin in patients with relapsed/refractory T-Cell lymphoma: final results from a phase I/II open label multi-center study. Blood 2021;138:1365

[107] Marchi E,Montanari F.The integration of PD1 blockade with epigenetic therapy is highly active and safe in heavily treated patients with T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).JCO2020;38:8049-8049

[108] Scarfò I,Maus MV.CAR-based approaches to cutaneous T-Cell lymphoma.Front Oncol2019;9:259 PMCID:PMC6477509

[109] Biotech L. Legend biotech announces FDA clinical hold of its phase 1 clinical trial for LB1901. Available from: https://www.businesswire.com/news/home/20220215005555/en/Legend-Biotech-Announces-FDA-Clinical-Hold-of-its-Phase-1-Clinical-Trial-for-LB1901 [Last accessed on 28 June 2022].

[110] Alcantara M,June CH.CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells.Leukemia2018;32:2307-15 PMCID:PMC7433349

[111] Hucks GE,Dotti G.CD30-directed chimeric antigen receptor (CAR)-T cells for treatment of hodgkin lymphoma and non-hodgkin lymphoma in pediatric patients.Blood2021;138:2829

[112] Non-Hodgkin’s Lymphoma Pathologic Classification Project. National cancer institute sponsored study of classifications of non-hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage.Cancer1982;49:2112-35

[113] Choi S,Lam N,Vanasse D.Design and assessment of novel anti-cd30 chimeric antigen receptors with human antigen-recognition domains.Hum Gene Ther2021;32:730-43 PMCID:PMC8312022

[114] Ramos CA,Beaven AW.Anti-CD30 CAR-T cell therapy in relapsed and refractory hodgkin lymphoma.J Clin Oncol2020;38:3794-804 PMCID:PMC7655020